Search the Newsreel

Gilead refreshes ADC biomarker collab with Nucleai

Gilead Sciences has renewed its collaboration with Israel-based Nucleai to apply Nucleai's AI-powered Tissue Intelligence platform for spatial biomarker generation and translational insights in Gilead's antibody-drug conjugate (ADC) clinical development programs. Nucleai's platform analyzes large datasets of H&E and IHC images, integrating computational pathology, …

Cardinal Capital Management Inc. Purchases 440,770 Shares of Gildan Activewear, Inc. $GIL

If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today

Gilead Sciences (NASDAQ: GILD) has significantly outpaced the market over the past two decades, yielding an average annual return of 11.31%. An initial investment of $1000 in GILD stock 20 years ago would now be valued at $8,488.28. This performance highlights the substantial impact …

Ermenegildo Zegna NV (ZGN) Stock Down 4.4% but Still Overvalued -- GF Score: 82/100

Ermenegildo Zegna NV (ZGN) shares recently declined by 4.4% and are currently trading at $14.15, which is 18.5% above its GF Value™ estimate, indicating it is overvalued. Despite a strong GF Score™ of 82/100, driven by high momentum and growth, the company faces challenges …

Gilead Sciences (GILD) EVP converts 6,002 RSUs, with 2,908 shares withheld

Gilead Sciences, Inc.'s EVP, Keeley M Cain Wettan, reported the conversion of 6,002 restricted stock units (RSUs) into common stock on August 10, 2026. Of these, 2,908 shares were withheld at $133.06 per share to cover exercise price or tax liability. Following this transaction, …

Gilead Sciences Inc. stock outperforms competitors on strong trading day

Gilead Sciences Inc. (GILD) saw its stock advance by 2.04% to $135.77 on Tuesday, outperforming the broader market which experienced a decline. The S&P 500 Index fell 0.32% and the Dow Jones Industrial Average fell 0.34% on the same trading day. Gilead Sciences Inc. …

Gilead Sciences options activity points to institutional conviction on 2026 upside

Options traders are showing strong institutional conviction for upside in Gilead Sciences through 2026, with a high call bias and significant call spread activity. This suggests investors expect the stock to rise to the $135-$150 range, supported by strong technicals and fundamentals despite some …

Gildan Activewear Inc. stock rises Tuesday, outperforms market

Gildan Activewear Inc. (GIL) saw its stock rise by 1.68% to C$81.50 on Tuesday, outperforming the Canadian market as the S&P/TSX Composite Index rose by 0.05%. Despite the gain, the company's stock closed 18.9% below its 52-week high achieved on February 13th.

BNP Paribas Downgrades Ermenegildo Zegna to Underperform From Neutral, Price Target is $12.20

BNP Paribas has downgraded Ermenegildo Zegna N.V. (ZGN) from "Neutral" to "Underperform" and set a new price target of $12.20. This analyst action reflects a less optimistic outlook on the luxury apparel company's stock. The article also provides recent news headlines related to Ermenegildo …

Handelsbanken Fonder AB Has $123.19 Million Stake in Gilead Sciences, Inc. $GILD

Handelsbanken Fonder AB decreased its stake in Gilead Sciences by 7.2% in the second quarter, now holding 975,089 shares valued at approximately $123.2 million. Other institutional investors have adjusted their positions, with collective institutional ownership standing at 83.67%. Gilead Sciences reported strong quarterly revenues …

E. Ohman J or Asset Management AB Has $5.66 Million Stock Holdings in Gilead Sciences, Inc. $GILD

E. Ohman J or Asset Management AB significantly reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 88.3% during the second quarter, now holding 44,792 shares valued at $5.66 million. Despite this, other institutional investors have slightly increased their holdings. Analysts currently rate GILD …

Rosen Law Firm Encourages Gildan Activewear Inc. Investors to Inquire About Securities Class Action Investigation - GIL

The Rosen Law Firm is investigating potential securities claims on behalf of Gildan Activewear Inc. (NYSE: GIL) shareholders. This investigation follows a short seller report from Jehoshaphat Research alleging misleading business information and financial engineering by Gildan, which caused the company's NYSE-listed shares to …

GILD- An Attractive Biotech Stock with Solid Base Revenue Growth

Gilead Sciences Inc. (GILD) just reported June quarter revenue up 10.2% from last year to $7.8 billion, ahead of estimates. Due to an $11.2 billion one-time write-off of acquired in-process R&D, they reported a $6.75 per share pro forma loss. But that was smaller …

Gildan Investor News: If You Have Suffered Losses in Gildan Activewear Inc. (NYSE: GIL), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims on behalf of Gildan Activewear Inc. (NYSE: GIL) shareholders due to allegations of materially misleading business information. This investigation follows a short seller report from Jehoshaphat Research, which questioned Gildan's organic growth and sales practices, …

Gilead Sciences, Inc. Revenue Breakdown – SIX:GILD

Gilead Sciences, Inc. generated 23.34 billion CHF in revenue last year. Its top-performing segment, Human Immunodeficiency Virus, contributed 16.45 billion CHF, a decrease from the previous year. The United States was the largest regional contributor, accounting for 16.55 billion CHF.

Gildan Activewear Stock And 2 Apparel Names Shaped By New US Tariffs

Noticias de acciones de Gilead Sciences Inc (GILD)

Should Gilead’s Swing to a Full‑Year Loss Outlook Require Action From Gilead Sciences (GILD) Investors?

Gilead Sciences recently reported a significant net loss of US$10.50 billion in Q2 2026, alongside cutting its full-year earnings outlook despite higher revenue. This shift to a projected full-year loss raises questions about how the company will balance investment, capital returns, and future financing, …

Gilead Sciences Inc (GILD) Aktuelle Aktien-News

Gildan Activewear, Inc. (NYSE:GIL) Given Average Rating of "Moderate Buy" by Brokerages

Gildan Activewear, Inc. (NYSE:GIL) has received an average "Moderate Buy" rating from brokerages, with 13 out of 16 analysts recommending a buy and three suggesting a hold. The average 12-month price target is $79.07. The company recently reported strong quarterly earnings of $1.28 per …

Arcus Biosciences (NYSE: RCUS) gets 24.7% ownership from Gilead

Gilead Sciences, Inc. has reported a beneficial ownership of 24.7% in Arcus Biosciences, Inc. (NYSE: RCUS), holding 31,424,760 shares out of 127,333,376 outstanding. This stake was built through multiple equity purchases dating back to 2020 and is linked to an Option, License and Collaboration …

Gildan Activewear Inc. (GIL.TO) stock price, news, quote and history

GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength

Gilead Sciences, Inc. GILD used its second-quarter 2026 call to emphasize stronger base-business growth, led by HIV, PrEP, Trodelvy and Livdelzi, while outlining a busy second-half launch calendar. Non-GAAP loss per share was $6.75, better than the Zacks Consensus Estimate for a loss of …

Czech National Bank Raises Stock Holdings in Gilead Sciences, Inc. $GILD

The Czech National Bank increased its stake in Gilead Sciences (NASDAQ:GILD) by 4.6% in Q2, bringing its total holdings to 353,398 shares valued at $44.6 million. Gilead Sciences reported Q2 revenue of $7.8 billion, exceeding analyst expectations, despite a reported loss due to acquisition …

PensionDanmark Pensionsforsikringsaktieselskab Purchases 25,515 Shares of Gilead Sciences, Inc. $GILD

PensionDanmark Pensionsforsikringsaktieselskab increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.3% in the second quarter, acquiring an additional 25,515 shares and bringing their total holdings to 233,799 shares valued at $29.54 million. This article details various institutional investor activities, recent positive and negative …

NewEdge Advisors LLC Buys 231,715 Shares of Gilead Sciences, Inc. $GILD

NewEdge Advisors LLC significantly increased its stake in Gilead Sciences (NASDAQ:GILD) by 144.2% in the first quarter, purchasing an additional 231,715 shares, bringing their total holdings to 392,435 shares valued at $54.7 million. This move is part of broader institutional investor activity in GILD …

Assenagon Asset Management S.A. Boosts Stock Holdings in Gilead Sciences, Inc. $GILD

Assenagon Asset Management S.A. significantly increased its stake in Gilead Sciences, Inc. by 346.5% in the second quarter, now owning 2,287,888 shares worth $289,052,000. Other institutional investors also adjusted their positions in the biopharmaceutical company. Gilead Sciences reported strong Q2 revenue of $7.8 billion, …

What Is Supporting Gildan Activewear (TSX:GIL) Recent Business Strength?

Gilead Sciences (GILD) Could Be Trading At A 20% Discount Following Raised Guidance

Gilead Sciences (NASDAQ: GILD) sets up automatic shelf for wide range of securities

Gilead Sciences has filed an automatic shelf registration statement on Form S-3, enabling it to offer a wide range of securities, including debt, common stock, preferred stock, and warrants, from time to time. This broad filing allows the company flexibility in future fundraising, with …

Ermenegildo Zegna N.V. (NYSE:ZGN) Given Average Recommendation of "Moderate Buy" by Analysts

Analysts have assigned Ermenegildo Zegna N.V. (NYSE:ZGN) an average "Moderate Buy" rating, with five buy and four hold recommendations. The average 12-month price target is $13.23, which is below its current trading price of $15.18. Recent analyst actions show mixed but generally positive sentiment, …

KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments

Kymera Therapeutics, Inc. KYMR reported a second-quarter 2026 loss of 62 cents per share, narrower than the Zacks Consensus Estimate of a loss of 64 cents. The company posted a loss of 95 cents in the year-ago period. Revenues surged to $65 million from …

Why Did Ermenegildo Zegna (NYSE:ZGN) Climb to a New High?

Ermenegildo Zegna (NYSE:ZGN) is a vertically integrated luxury fashion business with global operations in retail, textile manufacturing, and premium apparel. The article notes the company's stock climbing to a new high, and provides a brief overview of its products, operational reach across various international …

Gildan Activewear Inc. stock rises Thursday, outperforms market

Gildan Activewear Inc. (GIL) saw its stock rise by 0.20% to C$81.60 on Thursday, outperforming the Canadian market as the S&P/TSX Composite Index fell by 0.03%. The company's stock closed 18.8% below its 52-week high of C$100.44, which was reached on February 13th.

Gilead Sciences: A Strong Quarter Hidden Behind A Bottom-Line Loss (NASDAQ:GILD)

Scotiabank Predicts Stronger Earnings for Gildan Activewear